Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 2,285,637 |
|
|||||
| News | - | ||||||
| Day High | 4.26 | Low High |
|||||
| Day Low | 4.02 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Savara Inc | SVRA | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.03 | -0.73% | 4.08 | 18:20:39 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 4.12 | 4.02 | 4.26 | 4.09 | 4.11 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 13,593 | 2,285,637 | US$ 4.12 | US$ 9,424,141 | - | 2.56 - 5.70 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:20:38 | formt | 620 | US$ 4.08 | USD |
Savara Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 565.03M | 138.15M | - | 0 | -54.7M | -0.40 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Savara News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SVRA Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.20 | 4.27 | 4.00 | 4.12 | 890,233 | -0.12 | -2.86% |
| 1 Month | 4.78 | 5.31 | 4.00 | 4.55 | 869,911 | -0.70 | -14.64% |
| 3 Months | 5.47 | 5.59 | 4.00 | 4.76 | 852,003 | -1.39 | -25.41% |
| 6 Months | 3.82 | 5.70 | 3.72 | 4.71 | 925,845 | 0.26 | 6.81% |
| 1 Year | 2.57 | 5.70 | 2.56 | 4.20 | 748,737 | 1.51 | 58.75% |
| 3 Years | 1.80 | 5.70 | 1.02 | 3.10 | 431,055 | 2.28 | 126.67% |
| 5 Years | 10.85 | 11.39 | 0.69 | 2.68 | 702,676 | -6.77 | -62.40% |
Savara Description
| Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). |
